Whole-Exome Sequencing Market Size, Share and Trends Analysis, By Product and Service (Instruments, Kits and Reagents, Software & Bioinformatics Solutions, and Service), By Technology (Sequencing Platforms and Exome Capture Methods), By Application, By End-Use, and By Region, Forecast 2025-2032

Whole-Exome Sequencing Market Overview and Key Insights:

Whole-exome sequencing market size reached USD 440.6 million in 2024 and is expected to register a revenue CAGR of 18.1% during the forecast period. Whole exome sequencing (WES) is a next-generation sequencing (NGS) technique that concurrently tests the protein-coding sections of all patient’s genes, commonly known as the exome. The exome comprises around 1% of a patient’s genome.

Market Drivers:

DNA sequencing determines the order of DNA building blocks (nucleotides) in an individual’s genetic code, advancing genetic research and serving as one method for testing genetic illnesses. It helps to understand the genetic basis of numerous rare and complex diseases. Clinicians use whole-exome sequencing (WES) to diagnose bone and muscle disorders such as muscular dystrophy and osteogenesis imperfecta. According to the National Organization for Rare Disorders (NORD), Duchenne muscular dystrophy (DMD) is an uncommon muscle ailment, yet it is one of the most common hereditary conditions, affecting roughly one in every 3,500 male births globally. It is commonly identified between the ages of three and six. Muscular dystrophies are made up of around 30 distinct hereditary disorders.

Whole exome sequencing can provide information on all protein-coding areas of the genome, making it an effective method for identifying germline and somatic alterations in tumor samples. In comparison to targeted sequencing, WES has the advantage of being able to elucidate a sample’s entire exome profile and provide information on low-frequency mutations that can together underlie a complex phenotypic appearance.

On February 2025, Roche introduced its patented, revolutionary sequencing by expansion (SBX) technique, ushering in a new age of next-generation sequencing. SBX chemistry, when paired with a unique sensor module, provides ultra-fast, high-throughput sequencing that is both adaptable and scalable for a variety of applications. SBX technology’s adaptability makes it suited for a wide range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing.

Market Opportunity:

Integration with Artificial Intelligence (AI) and machine learning acts as opportunities for whole-exome sequencing market. Variant relevance in WES data is determined by cross-referencing population frequency databases, estimated functional effect scores, and in silico protein structure models. ClinPred improves this approach by leveraging ML algorithms trained on databases like ClinVar and gnomAD, resulting in extremely accurate pathogenicity scores for coding variants commonly found in WES datasets. DANN uses deep learning to increase annotation accuracy for both coding and non-coding variants by modeling non-linear correlations between genomic features.

AI-based methods can speed up the examination of candidate variations in WES by combining data from numerous sources (e.g., OMIM, PolyPhen-2, and SIFT) and evaluating them based on their pathogenic likelihood. A streamlined methodology reduces the chance of missing crucial data, allowing for faster and more accurate interpretation of exome sequencing results in clinical and research settings.

On September 2025, BioAro, a global leader in precision health and genomics, has launched its innovative AI-powered PanOmiQ platform. Its powerful AI-powered analytics include Whole Exome Sequencing and microbiome analysis, which encompass skin, mouth, gut, and vaginal microbiomes in real time. This complete genomics method enables academics and healthcare practitioners to acquire a better understanding of the interaction between genetics and microbiomes, thereby enhancing the field of precision health. PanOmiQ improves our understanding of how microbial ecosystems affect human health by including microbiome analyses.

Recent Trends:

Emerging trends include high-throughput sequencing & cost reductions, improved target enrichment & library preparation, enhanced bioinformatics & data interpretation tools, and emergence of direct-to-consumer (DTC)/decentralized testing.

Experiments with next-generation sequencing (NGS) continue to allow for a dramatic shift in how genetic variation is found and used. Scientists can utilize a variety of application systems to assess the value of their sequencing data and discover areas of interest. Methods such as FastQC make it simple to perform quality control checks on data in a FastQ file. Data with poor quality is typically removed from the FastQ file. Trimmomatic, for example, is a way for doing this function. Open-source software packages like as the Genome Analysis Toolkit (GATK) and the Burrows-Wheeler Aligner (BWA) allow researchers to assess metrics from their sequencing operations and clean sequences as needed for quality control. Picard Alignment Summary metrics are a popular way to assess data quality.

On May 2025, QIAGEN stated that it has reached a definitive agreement to purchase Genoox, a provider of AI-powered software that allows clinical labs to scale and accelerate the processing of complicated genetic testing. Franklin, Genoox’s primary cloud-based community platform, will be added as part of the transaction. Franklin enables labs to examine next-generation sequencing (NGS) data, ranging from targeted gene panels to whole exome and genome sequencing (WES/WGS), and provide real-time, AI-driven insights to support clinical decision-making.

Restraints & Challenges:

Whole-exome sequencing has significant drawbacks, including limited taxonomic precision, copy number variations in rRNA genes, and taxonomic biases due to PCR amplification. Furthermore, the idea that amplicon-based approaches can only detect known alterations like SNPs and insertions/deletions (InDels) is unduly simplistic. While amplicon-based approaches are effective for finding hotspots, they are not limited to this use.

The exome capture process in the WES may induce technical biases. It cannot cover all areas of interest. Many target regions resist enrichment, making complete capture impossible. It can identify secondary or inadvertent findings, like as mutations unrelated to the condition under examination, raising important ethical and practical concerns regarding how to handle these findings.

Product and Service Segment Insights and Analysis:

Based on the product and service, whole-exome sequencing market is segmented into instruments, kits & consumables, software & bioinformatics solutions, and services.

Instruments segment contributed the largest market share in 2024. Exome sequencing uses a capture-based technology to detect changes in the coding regions of genes that alter protein function. Researchers apply exome capture methods such as PCR, hybrid capture, and molecular inversion probes, but they rely most often on in-solution capture methods because these are the most efficient. Exome sequencing enables researchers to identify the genetic basis and harmful mutations in Mendelian disorders, which usually arise from a single mutation. This procedure delivers results more efficiently than traditional diagnostic methods that evaluate each gene separately. Researchers are also increasingly applying this technique in cancer studies, since many tumors arise from somatic changes in specific genes rather than inherited germline mutations.

On May 2024, Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, has announced the release of RNAseq, a novel RNA sequencing test for Whole Exome and Whole Genome Sequencing (WE/WGS). The company also decreased the typical turnaround time for WES and WGS to three weeks and continues to offer quick testing with written reports in as little as five days. In addition, Baylor Genetics has introduced four new next-generation sequencing panels for immunodeficiency, cerebral palsy, connective tissue, and skeletal abnormalities.

Technology Segment Insights and Analysis:

Based on the technology, whole-exome sequencing market is segmented into sequencing platforms and exome capture methods.

Sequencing platforms segment contributed the largest market share in 2024. It is further sub segmented into short-read sequencing and long-read exome sequencing. The environment of DNA sequencing is constantly evolving, with new players and ways for decoding genetic information developing. The most often utilized approach is short read sequencing, which has read lengths ranging from 50 to 300 base pairs. It encompasses a variety of ways for deciphering genetic information, each with its own approach. The systems offered are broadly classified into three categories: sequencing by synthesis (SBS), sequencing by binding (SBB), and sequencing by ligation (SBL). These applications benefit from short read sequencing’s high accuracy and throughput, which enables deep investigation of genetic variants such single nucleotide polymorphisms (SNPs) and tiny insertions or deletions within a genome.

On July 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, has announced the release of the latest edition of DRAGEN software for analyzing next-generation sequencing data. DRAGEN 4.2 improves accuracy while maintaining its well-known flexibility and scalability, allowing for more efficient workflows and the extraction of valuable insights from genetic data. DRAGEN, with its capacity to perform high-quality, rapid, accurate, and complete NGS analysis processes, is well-suited to assist the healthcare and research industries in their undertakings.

Application Segment Insights and Analysis:

Based on the application, whole-exome sequencing market is segmented into clinical diagnostics, drug discovery & development, population genomics & translational research, and agrigenomics/veterinary research.

Clinical diagnostics segment contributed the largest market share in 2024. It is further sub segmented into rare genetic diseases, oncology, neurological & cardiovascular disorders, and reproductive health. According to World Health Organization (WHO), every year, around 5 million people worldwide are diagnosed with epilepsy. In high-income countries, epilepsy is projected to affect 49 out of every 100,000 persons. In low- and middle-income nations, the figure can reach 139 per 100,000. If appropriately diagnosed and treated, up to 70% of persons with epilepsy may be able to live seizure-free. With proper antiseizure medication, up to 70% of persons with epilepsy could achieve seizure-free status. After two years without seizures, discontinuing antiseizure medication should be considered, considering pertinent clinical, social, and personal variables.

On April 2025, GeneDx, a leader in advancing health outcomes through genomic insights, announced its commercial expansion into Inborn Errors of Immunity (IEI)—a group of nearly 500 genetic disorders that compromise immune function and heighten susceptibility to infections, autoimmunity, and inflammatory diseases. This strategic move strengthens GeneDx’s mission to enhance patient outcomes by offering exome and genome testing solutions to a broader patient population, now extending to those with inherited immunological conditions.

Geographical Outlook:

Whole-exome sequencing market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Whole-Exome Sequencing Market:

North America is registered to have highest market share in whole-exome sequencing market in 2024. Advancements in sequencing technologies and the growing demand for personalized and precision medicine primarily drive this field. Genome analysis and sequencing will deliver exciting innovations and outcomes across a wide range of study areas in the future. As sequencing technology continues to advance, researchers improve diagnostic approaches. These techniques have become so advanced that pregnant women can now avoid invasive methods like amniocentesis to detect chromosomal abnormalities in the fetus and instead obtain results through a simple blood test. The development of low-cost, high-performance sequencing technologies will further expand the scope of genomic research and applications. In the coming years, researchers aim to enhance efficiency, accuracy, and processing speed. Scientists use sequencing data to develop new diagnostic and prognostic tools.

On October 2024, Element Biosciences, Inc., a developer of cutting-edge technologies to empower science, has introduced Trinity, an innovative solution that simplifies target capture sequencing by eliminating or moving traditionally time-consuming steps to the AVITI System and giving customers the option to significantly reduce hybridization time without sacrificing cost or quality. Element’s inaugural annual virtual event, the first Trinity product is an exome target capture tool that helps researchers to focus sequencing on the most relevant genomic areas, saving time and money when compared to whole genome sequencing (WGS).

Asia Pacific Whole-Exome Sequencing Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by advancement in sequencing technologies and increased funding & government/public health initiatives. NGS has emerged as a possible game changer in cancer care, as the Asia-Pacific (APAC) region continues to experience an increasing cancer burden, imposing clinical, societal, and economic costs. NGS enables the delivery of personalized cancer care through tumour profiling, and multiple studies in APAC have shown that it improves patient outcomes by shortening time to results, identifying more patients for matched therapies and clinical trials, and lowering diagnosis costs when compared to current practice.

Medical associations in APAC markets, including China, Japan, and South Korea, have developed clinical practice guidelines to promote NGS best practices. The Japanese Society of Medical Oncology, Japanese Society of Clinical Oncology, and Japanese Cancer Association collaborated to establish clinical guidelines for using NGS for cancer profiling and treatment. This guide provides recommendations for selecting NGS tests based on their characteristics, collecting and managing samples, educating patients, handling test findings, and building NGS systems and working groups within hospitals.

On April 2025, Vgenomics, a precision health company, and Meril Genomics, a diagnostics and molecular biology supplier, have formed a cooperation to provide complementary advanced genomic diagnostics to hospitals and research facilities across India. This collaboration brings together Vgenomics’ expertise in bioinformatics, AI-driven research, and translational genomics with Meril Genomics’ skills in diagnostics and molecular biology. Furthermore, the program incorporates Whole Exome Sequencing (WES) for detecting uncommon diseases, which will benefit India’s nearly 70 million affected persons.

Competition Analysis:

Whole-exome sequencing market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in whole-exome sequencing market report are:

• Illumina, Inc.
• Integrated DNA Technologies, Inc
• CD Genomics
• CENTOGENE GmbH
• Caris Life Sciences
• Thermo Fisher Scientific Inc.
• Celemics, Inc.
• PreventionGenetics
• Hoffmann-La Roche Ltd
• QIAGEN
• GENEWIZ from Azenta
• Source BioScience
• Admera Health
• Twist Bioscience

Strategic Developments in Whole-Exome Sequencing Market:

• In August 2023, Almac Diagnostic Services, a member of the Almac Group, has announced plans to expand its Next Generation Sequencing (NGS) capabilities for BioPharma partners, following the acquisition and installation of the first Illumina NovaSeq X Plus instrument in Northern Ireland and across the island of Ireland. This investment in Illumina’s latest and most powerful equipment expands Almac’s NGS portfolio of DNA Sequencing Service options, which includes Whole Genome Sequencing, Whole Exome Sequencing, and a variety of RNA Sequencing Service offers for Biomarker Discovery projects.
• In January 2023, QIAGEN has established an exclusive strategic agreement with California-based population genomics leader Helix to enhance companion diagnostics for genetic disorders. The alliance will make use of the Helix Laboratory technology, which received the first de novo class II permission from the US Food and Drug Administration for a whole exome sequencing technology.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Whole-Exome Sequencing Market Report:

Whole-Exome Sequencing market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product and Service Outlook (Revenue, USD Million; 2022-2032)
  • Instruments
  • Kits & Consumables
  • Software & Bioinformatics Solutions
  • Services

• Technology Outlook (Revenue, USD Million; 2022-2032)
  • Sequencing Platforms
    • Short-read sequencing
    • Long-read exome sequencing
  • Exome Capture Methods
    • Hybrid capture
    • Amplicon-based methods

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Clinical Diagnostics
    • Rare genetic diseases
    • Oncology
    • Neurological & cardiovascular disorders
    • Reproductive health
  • Drug Discovery & Development
    • Population Genomics & Translational Research
    • Agrigenomics / Veterinary Research

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospitals & Clinical Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Government & Public Health Programs

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about Whole-Exome Sequencing market report